Description
EORTC ‘s research into adult Leukemia is mainly concerned with improving the outcomes of patients with leukemias or related hematologic malignancies. We operate through clinical trials, such as large standard-practice changing phase III studies, and run strong translational research programmes analysing epigenetic therapy in acute myeloid leukemia or myelodysplastic syndrome. EORTC works in collaboration with other national and international study groups, particularly the GIMEMA. We are also developing robust survivorship studies, taking advantage of the large number of patients already included in phase III research.
Main Achievements
Demonstrated the superiority of allogeneic vs autologous stem cell transplantation vs intensive consolidation in Acute Myeloid Leukemia (AML) younger patients More information
Showed high-dose cytarabine increased remission and survival rates as compared to standard-dose cytarabine, especially in AML patients younger than 46 years old More information
Found that first-line monotherapy with low-dose Gemtuzumab Ozogamicin, as compared with Best Supportive Care, significantly improved OS in older AML patients who were ineligible for intensive chemotherapy More information
Demonstrated decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL More information
Related Projects
- RP-1479 (SPARTA): The Survivorship Project to understand and to improve long-Term outcomes for Acute myeloid leukemia patients.
(Project leaders: F. Efficace / F. Baron)
The research project is ongoing.
Research Group
Group documents-
Chair
Frédéric Baron
C.H.U. Sart-Tilman
Liège, Belgium
-
SecretaryHeiko Becker
Universitaetsklinikum Freiburg
Freiburg, Germany
-
TreasurerLaimonas Griskevicius
Vilnius University Hospital Santariskiu Clinics
Vilnius, Lithuania